close 73% van de retail rekeningen verliezen gelden met de handel in CFD`s bij deze aanbieder. Investeringen zijn risicovol en zijn niet geschikt voor alle beleggers. CFD`s zijn complexe instrumenten met een hoog risico om snel gelden te verliezen vanwege het hefboomeffect. 73% van de retail beleggers lijdt verlies bij het handelen in CFD`s met deze aanbieder. Het is belangrijk dat u goed begrijpt hoe CFD`s werken en dat u nagaat of u zich het hoge risico op verlies kunt permitteren.
ZoekenZoeken
Change languageNederlands
Dashboard

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

LLY

965.93

+4.72%↑

JNJ

187.89

+0.86%↑

UNH

321.52

-0.8%↓

NVS

127.05

+0.61%↑

ABT

125.76

-0.34%↓

Home・Aandelen Lijst・Karyopharm Therapeutics Inc
Search

Karyopharm Therapeutics Inc

Gesloten

SectorGezondheidszorg

5.33 3.09

Strong Buy

Prijsupdate 10 nov 2025, 20:57 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

5.02

Max

5.39

Belangrijke statistieken

By Trading Economics

Inkomsten

4.1M

-33M

Verkoop

6.1M

44M

EPS

-3.82

Winstmarge

-75.213

Werknemers

279

EBITDA

9.2M

-15M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+168.02% upside

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-5.6M

97M

Vorige openingsprijs

2.24

Vorige sluitingsprijs

5.33

Nieuwssentiment

By Acuity

50%

50%

170 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

5.9501 / 7.66 Steun & Weerstand

Karyopharm Therapeutics Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

10 nov 2025, 22:17 UTC

Winsten

Commonwealth Bank Posts Flat 1Q Profit Despite Margin Pressure -- Update

DJ

Lezen

10 nov 2025, 21:48 UTC

Winsten

Commonwealth Bank Posts Flat 1Q Profit Despite Margin Pressure

DJ

Lezen

10 nov 2025, 23:44 UTC

Marktinformatie

Gold Edges Higher on Signs of Possible End to U.S. Govt Shutdown -- Market Talk

DJ

Lezen

10 nov 2025, 23:43 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen, Earnings Hopes -- Market Talk

DJ

Lezen

10 nov 2025, 22:20 UTC

Acquisities, Fusies, Overnames

Paramount Stock Climbs as Forecast Beats Estimates -- Barrons.com

DJ

Lezen

10 nov 2025, 21:50 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

DJ

Lezen

10 nov 2025, 21:50 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

DJ

Lezen

10 nov 2025, 21:49 UTC

Acquisities, Fusies, Overnames

Paramount Stock Climbs as Forecast Beats Estimates -- Barrons.com

DJ

Lezen

10 nov 2025, 21:45 UTC

Winsten

PepsiCo and 3 Other Defensive Stocks to Ride Out a Vulnerable Market -- Barrons.com

DJ

Lezen

10 nov 2025, 21:40 UTC

Winsten

Friedman Industries 2Q EPS 32c >FRD

DJ

Lezen

10 nov 2025, 21:18 UTC

Winsten

Occidental Petroleum 3Q Adj EPS 64c >OXY

DJ

Lezen

10 nov 2025, 21:17 UTC

Winsten

Occidental Petroleum 3Q EPS 65c >OXY

DJ

Lezen

10 nov 2025, 21:17 UTC

Winsten

Occidental Petroleum 3Q Rev $6.72B >OXY

DJ

Lezen

10 nov 2025, 21:16 UTC

Winsten

Occidental Petroleum 3Q EPS 65c >OXY

DJ

Lezen

10 nov 2025, 21:16 UTC

Winsten

Occidental Petroleum 3Q Adj EPS 64c >OXY

DJ

Lezen

10 nov 2025, 20:30 UTC

Marktinformatie

Expected End to U.S. Government Shutdown Helps Lift Crude -- Market Talk

DJ

Lezen

10 nov 2025, 20:24 UTC

Marktinformatie

Hopes For New Government Data Lift Gold -- Market Talk

DJ

Lezen

10 nov 2025, 20:08 UTC

Marktinformatie

U.S. Natural Gas Settles Higher As Colder Weather Arrives -- Market Talk

DJ

Lezen

10 nov 2025, 19:49 UTC

Marktinformatie

Mexican Industrial Production Seen Soft in September -- Market Talk

DJ

Lezen

10 nov 2025, 19:43 UTC

Winsten
Acquisities, Fusies, Overnames

Paramount Earnings Come Amid Warner Bros Merger Reports -- Barrons.com

DJ

Lezen

10 nov 2025, 19:16 UTC

Winsten

Charles Schwab's CEO Is Worried About Prediction Markets. What He Told Thousands of Financial Advisors. -- Barrons.com

DJ

Lezen

10 nov 2025, 17:58 UTC

Acquisities, Fusies, Overnames

Eli Lilly Stock on Pace for a New High. The Zepbound Maker Just Got a Big Upgrade. -- Barrons.com

DJ

Lezen

10 nov 2025, 17:56 UTC

Marktinformatie

Oil Futures Edge Up in Rangebound Trade -- Market Talk

DJ

Lezen

10 nov 2025, 17:32 UTC

Winsten

Barrick Looking to Reset Safety Culture Following Fatalities -- Interview

DJ

Lezen

10 nov 2025, 17:30 UTC

Winsten

Barrick Continues Efforts to Free Workers Jailed in Mali -- Interview

DJ

Lezen

10 nov 2025, 17:20 UTC

Marktinformatie
Winsten

Basic Materials Roundup: Market Talk

DJ

Lezen

10 nov 2025, 17:20 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Health Care Roundup: Market Talk

DJ

Lezen

10 nov 2025, 17:00 UTC

Winsten

Barrick Looks to Get Handle On North American Operations, Find Growth -- Interview

DJ

Lezen

10 nov 2025, 17:00 UTC

Winsten

Barrick Expects Strong Cash Flows Ahead With Commodity Prices at Current Levels, CFO Says in Interview

DJ

Lezen

10 nov 2025, 17:00 UTC

Winsten

Barrick Conducting Bottom-Up Review of Nevada Ops, Looking for Growth Opportunities

DJ

Lezen

Peer Vergelijking

Prijswijziging

Karyopharm Therapeutics Inc Prognose

Koersdoel

By TipRanks

168.02% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 13.83 USD  168.02%

Hoogste 21 USD

Laagste 6 USD

Gebaseerd op 6 Wall Street-analisten die 12-maands prijsdoelen bieden voor Karyopharm Therapeutics Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

6 ratings

5

Buy

1

Hold

0

Sell

Gebaseerd op 6 analisten die aandelenratings hebben gegeven aan Karyopharm Therapeutics Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.9501 / 7.66Steun & Weerstand

Korte Termijn

Bullish Evidence

Recent bullish events outweigh bearish events.

Gemiddeld Termijn

Strong Bearish Evidence

All events are bearish.

Lange Termijn

No Evidence

There are no events.

Sentiment

By Acuity

170 / 374 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Andere aandelen uit de sector

LLY

Eli Lilly and Co.

965.93

↑ +4.72%

JNJ

Johnson and Johnson

187.89

↑ +0.86%

UNH

UnitedHealth Group Inc

321.52

↓-0.8%

NVS

Novartis AG

127.05

↑ +0.61%

ABT

Abbott Laboratories

125.76

↓-0.34%
help-icon Live chat